SAN
JOSE, Calif., Feb. 4, 2025
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")
(NASDAQ: ANIX), a biotechnology company focused on the treatment
and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, was
featured on CW39's H-Town Live, where he discussed the Company's
pioneering efforts in breast cancer prevention.
During the segment, Dr. Kumar highlighted Anixa's groundbreaking
research in developing a novel breast cancer vaccine in
collaboration with the Cleveland Clinic. The vaccine, currently in
clinical trials, aims to prevent triple-negative breast cancer
(TNBC), the most aggressive and difficult-to-treat form of the
disease. By targeting a specific protein found in TNBC cells but
absent in normal breast tissue, the vaccine seeks to stimulate the
immune system to recognize and eliminate cancer cells before they
can develop into full-blown tumor mass.
"We are dedicated to advancing science that can fundamentally
change the way we approach breast cancer," said Dr. Kumar during
the interview. "Our vaccine is designed to prevent the disease
before it starts, potentially eliminating the need for invasive
treatments such as chemotherapy and surgery in the future."
The discussion also addressed the broader impact of Anixa's
research on the field of oncology, as well as the importance of
continued innovation in cancer prevention.
To watch Dr. Amit Kumar's full
interview on H-Town Live, please visit:
https://www.youtube.com/watch?v=b8r5mJsJn74.
For more information about Anixa Biosciences and its ongoing
clinical trials, please visit www.anixa.com.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-chairman--ceo-dr-amit-kumar-featured-on-cw39s-h-town-live-to-discuss-the-future-of-breast-cancer-prevention-302367010.html
SOURCE Anixa Biosciences, Inc.
